Loading clinical trials...
Loading clinical trials...
SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 as a treatment fo...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
GlaxoSmithKline
NCT05070845 · Primary Immune Thrombocytopenia
NCT07039422 · Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
NCT06533098 · Thrombocytopenia, Neonatal Alloimmune
NCT07007962 · Immune Thrombocytopenia
NCT07492693 · Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Detroit, Michigan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions